Table I.
Patient, disease, and transplantation characteristics by route of busulfan administration*.
| Oral busulfan n = 72 |
i.v. busulfan n = 59 |
Combined n = 131 |
|
|---|---|---|---|
| Age in years | 43 50 55 (49 ± 10) | 34 49 56 (45 ± 13) | 40 49 56 (47 ±11) |
| Sex | |||
| Female | 46% (33) | 53% (31) | 49% (64) |
| Male | 54% (39) | 47% (28) | 51% (67) |
| Diagnosis | |||
| AML/MDS/CMML | 61% (44) | 69% (41) | 65% (85) |
| ALL | 8% (6) | 10% (6) | 9% (12) |
| HL | 10% (7) | 3% (2) | 7% (9) |
| NHL | 8% (6) | 2% (1) | 5% (7) |
| CLL | 3% (2) | 3% (2) | 3% (4) |
| MM | 4% (3) | 2% (1) | 3% (4) |
| CML | 6% (4) | 10% (6) | 8% (10) |
| Disease status at AlloBMT | |||
| CR without MRD | 32% (23) | 46% (27) | 38% (50) |
| MRD | 25% (18) | 32% (19) | 28% (37) |
| Active disease | 43% (31) | 22% (13) | 34% (44) |
| Relatedness | |||
| Unrelated | 14% (10) | 83% (49) | 45% (59) |
| Related | 86% (62) | 17% (10) | 55% (72) |
| HCT-CI | 1 3 3 (2 ±2) | 1 2 4 (2 ± 2) | 1 2 4 (2 ± 2) |
| Transplantation year | |||
| 2004–2005 | 25% (18) | 14% (8) | 20% (26) |
| 2006 | 35% (25) | 22% (13) | 29% (38) |
| 2007 | 35% (25) | 20% (12) | 28% (37) |
| 2008–2009 | 6% (4) | 44% (26) | 23% (30) |
| First-dose AUC | 890 1066 1224 | 755 860 1066 | 823 993 1169 |
| (1082 ±269) | (938 ±259) | (1017 ± 273) |
a b c represent the lower quartile a, the median b, and the upper quartile c for continuous variables. x ± s represents the mean ± the standard deviation. Numbers after percentages are frequencies.
i.v., intravenous; AUC, area-under-the-concentration-curve; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CMML, chronic myelomonocytic leukemia; ALL, acute lymphoblastic leukemia; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; CML, chronic myelogenous leukemia; alloBMT, allogeneic bone marrow transplantation; CR, morphologic complete remission; MRD, minimal residual disease; HCT-CI, hematopoietic cell transplantation comorbidity index.